Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.47 |
| ▸ | CCR1 | P32246 | 9/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | WDR91 | A4D1P6 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20600984 | 1.00 | IDO1 (0.47) | IDO1CCR1CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL20600914 | 0.91 | CCR1 (0.42) | IDO1CCR1CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL20600913 | 0.91 | CCR1 (0.42) | IDO1CCR1CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL20601091 | 0.85 | MGLL (0.39) | CYP3A4ALDH1A1KDM4ESMN1; SMN2MGLL | |
| SCHEMBL20601048 | 0.84 | IDO1 (0.50) | IDO1CCR1CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL20601050 | 0.84 | IDO1 (0.50) | IDO1CCR1CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL20601118 | 0.84 | MGLL (0.42) | IDO1CCR1CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL20601120 | 0.84 | MGLL (0.42) | IDO1CCR1CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL20601141 | 0.83 | IDO1 (0.50) | IDO1CCR1CYP3A4ALDH1A1KDM4E | |
| SCHEMBL28347730 | 0.80 | KMT2A (0.53) | CCR1ALDH1A1KDM4ESMN1; SMN2WDR91 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10927078-B2 | Modulators of indoleamine 2,3-dioxygenase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-02-23 | — | — | US | disclosed |
| US-20200165201-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| EP-3645520-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-05-06 | — | — | EP | disclosed |
| WO-2019003141-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019003141-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165201-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, TPH1 | IDO1 1/4885CCR1 1565/4885CYP3A4 328/4885 |
| US-10927078-B2 | Modulators of indoleamine 2,3-dioxygenase | IDO1, IDO2, TPH1 | IDO1 1/4885CCR1 1565/4885CYP3A4 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.